消癌平注射液辅助治疗进展期胃癌的临床研究  

Clinical research on the complementary treatment of Xiaoaiping injection on patients with advanced gastric cancer

作　　者：王军艳[1] 陈建婷[1] Wang Junyan;Chen Jianting(Department of digestive medicine,second affiliated hospital of xi＇an medical college,xi＇an,shaanxi 710038,China.)

机构地区：[1]西安医学院第二附属医院消化内科,西安710038

出　　处：《中华普外科手术学杂志（电子版）》2018年第6期503-506,共4页Chinese Journal of Operative Procedures of General Surgery(Electronic Edition)

基　　金：陕西省卫计委科研基金资助项目(20160042616)~~

摘　　要：目的探讨消癌平注射液+卡培他滨联合奥沙利铂(XELOX)方案治疗进展期胃癌的临床效果。方法研究对象为2016年1月至2017年12月收治的80例进展期胃癌患者,采取随机数字表将其分成两组,每组40例。两组患者均给予XELOX方案化疗,消癌平组在此基础上联合给予消癌平注射液治疗。在完成2个周期治疗后对两组进行疗效评定,数据采取SPSS20. 0软件进行处理,两组短期疗效、不良反应发生情况均以百分率(%)表示,运用χ2检验;治疗前后血清炎症因子水平、外周血免疫细胞比例及EORTC QLQ-C30评分均用均值±标准差表示,采用独立t检验,以P <0. 05为差异有统计学意义。结果消癌平组有效率为80. 0%(32/40),与对照组的57. 5%(23/40)比较明显上升(P <0. 05)。两组治疗后血清IL-6、TNF-α、CRP浓度及外周血MDSCs、Treg占PBMC比例均较治疗前显著降低(P <0. 05),且以消癌平组减少更明显(P <0. 05)。两组治疗后EORTC QLQ-C30中躯体功能、角色功能、情绪功能、社会功能、总体健康各维度评分均较治疗前显著增加,症状维度评分较治疗前均显著下降(P <0. 05),且均以消癌平组改善更明显(P <0. 05)。两组不良反应比较差异无统计学意义(P> 0. 05)。结论消癌平注射液联合XELOX方案化疗能显,提高进展期胃癌的治疗效果,并能调节免疫细胞,改善炎症状态,提高患者的生存质量。Objective To explore the clinical efficacy of Xiaoaiping injection in the chemotherapy of xeloda and oxaliplatin （XELOX） on patients with advanced gastric cancer. Methods 80 cases with advanced gastric cancer treated in our hospital from January 2016 to December 2017 were divided into two groups on the basis of random number table, each with 40 cases. Both groups were treated with XELOX, while the Xiaoaiping group was administrated with Xiaoaiping injection additionally. The clinical efficacy after 2 courses of treatment was assessed. Data were processed in SPSS20.0. The short-term curative effect as well as adverse reactions were expressed in percentages （%） and compared by χ 2 test. And the inflammatory factors, proportion of peripheral blood immune cells and EORTC QLQ-C30 scores before and after treatment were indicated in mean value±standard deviation and compared by independent t test. A P 〈0.05 was regarded as significant difference. Results The effective rate of the Xiaoaiping group was significantly higher than the control group（80.00% vs. 57.50% P 〈0.05）. After treatment, a remarkable decrease in serum IL-6, TNF-α , CRP concentration, peripheral blood MDSCs and Treg accounted for the proportion of PBMC as compared with those before treatment was found in both groups （ P 〈0.05）, and the decrease of the Xiaoaiping group was more significant （ P 〈0.05）. After treatment, a great increase in EORTC QLQ-C30 dimensions including physical function, role function, emotional funtion, social function, general health scores was found n both groups, meanwhile a big decrease in symptom dimension score as compared with those before reatment was also found （ P 〈0.05）, and the improvement in the aforementioned indicators in the Xiaoaiping group was more significant （P 〈0.05）. No significant difference was found between the two groups in terms of adverse reactions （ P 〉0.05）. Conclusion In treating patients with advanced gastric cancer, the combination of Xiaoaiping i

关 键 词：胃肿瘤 药物疗法 联合 T淋巴细胞 调节 生活质量 消癌平注射液 

分 类 号：R735.2[医药卫生—肿瘤]